www.interpharma.co.th IP_OCS/010/2562 November 10, 2019 Subject Management’s discussion and analysis for the third quarter of 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited (“the

-1- Ref. POL. 028/2020 February 25, 2020 Re: Management Discussion & Analysis of S & P Syndicate Public Company Limited Dear The President The Stock Exchange of Thailand S & P Syndicate Public

S&P MD&A Q3-2017 -1- Ref. POL. 136/2017 November 13, 2017 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock Exchange of Thailand S & P

S&P MD&A 2017 -1- Ref. POL. 028/2018 February 23, 2018 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock Exchange of Thailand S & P Syndicate

S&P MD&A 2017-Revised Year In Comparison Table -1- Ref. POL. 028/2018 February 23, 2018 Re: Clarification of the Performance of S & P Syndicate Public Company Limited Dear The President The Stock

Microsoft Word - MD&A FY17 EN (1) February 26, 2018 To President, The Stock Exchange of Thailand Subject Notification on the difference of revenue from sales and net profit YOY by more than 20

(Translation) NEP-AC 002/2563 14 May 2020 Subject: Management Discussion and Analysis for Q1 end of 31 March 2020 To : The President The Stock Exchange of Thailand Operating Result NEP Realty and

November 11, 2020 Subject: Management’s Discussion and Analysis for the third quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries

longer than that of Q2/2018 from Long Quan Safe Food JSC (LQSF), Vietnam.  Total Contract Manufacturing Business (CMG) sales decreased 9% YoY.  Domestic Branded Business sales decreased 16% YoY.  Export

The Stock Exchange of Thailand 1. Analysis of Overall Operating Results and Financial Position of the Company and its subsidiary 1.1 Analysis of Overall Operating Results for the Company and its